VERU / Medical Leader Veru Catapults As FDA Preps To Discuss Cancer Drug For Covid

Veru Inc. (VERU) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0 more_horizontal

Veru Inc. (NASDAQ:VERU ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relati more_horizontal

Veru Inc. (VERU) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0 more_horizontal

Veru (NASDAQ: VERU ) just reported its fiscal second-quarter results. Veru reported a loss per share of 43 cents. more_horizontal

Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Veru (NASDAQ: VERU ) stock is getting a boost on Friday after the company revealed plans to sell its ENTADFI capsule business. That sale has the compa more_horizontal

MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-1 more_horizontal

Veru (NASDAQ: VERU ) stock is taking a beating on Friday after the FDA denied the company's request for EUA for its Covid-19 treatment. That rejection more_horizontal